Podcast appearances and mentions of Johnson Johnson

As bispecific antibodies (BsAbs) become more integrated into oncology care, much of the focus has been placed on clinical protocols and operational readiness. However, less attention has been paid to the patient and caregiver experience. In this episode, CANCER BUZZ explores how it feels physically and emotionally for patients to begin and continue BsAb therapy. Grounded in real-world insights, this discussion highlights the logistical and emotional challenges that arise during the step-up period and early treatment phases and identifies opportunities for care teams to better support patients throughout their journey.  In partnership with HOPA and APSHO. This program was made possible with support from Johnson & Johnson and Genentech. Guest:  Leslie Mader, RN, BSN, OCN  Patient Care Coordinator, Bispecific Drug Therapy and IEC Therapy, Hematology/Stem Cell Transplant  Vanderbilt Ingram Cancer Center "It decreased the amount of time they had to be in the clinic, you know, because a lot of these people we're getting them back to their regular lives where they can work, they can go to you know continue on with life. So anything that we can give that's in an injection, and anything that's targeted to decrease systemic reactions is better for the patient."  - Leslie Mader "They think, oh, this is great. I'm going to get through it with no problems. And then they get dose three or dose four, and they're like crap. You know, they get discouraged. But usually, you know, we have emergency drugs that we give them dexamethasone, and it usually resolves quickly."  - Lesie Mader Resources: A Blueprint for Successful Integration of Bispecific Antibodies   Delivery Models for Administering T-Cell-Engaging Bispecific Antibodies  Delivering T-Cell-Engaging Bispecific Antibodies: Frequently Asked Questions (FAQ) ACCC Office Hours Recording - Bispecific Antibodies: One BiTE at a Time     Bispecific Antibodies Checklist for Community Providers Using Bispecific Antibodies in Community Practice: Challenge and Opportunities Expanding Access to Cellular and Bispecific Therapies: Considerations and Recommendations   

The NHS became the world's first health system to commit to reaching net zero emissions in October 2020. But bold national commitments only become reality through the people doing the work at the point of care. In this Insight from Episode 104: Practicing Green Health, Emma Pascale Blakey, PhD, RN, Nurse Lead for Sustainability at NHS England, makes the case that nurses and midwives have a valuable perspective as researchers and scientists in this equation, and they are an invaluable resource when it comes to sustainability solutions. From drones delivering chemotherapy to the Isle of Wight, to health visitors cycling between family visits, to clinical procurement nurses influencing what equipment gets ordered, nurses are leading the way when it comes to sustainability.   To listen to this Insight clip's full episode, visit the SEE YOU NOW Podcast Episode 104: Practicing Green Health on APPLE, SPOTIFY, YOUTUBE, or your favorite streaming platform.   Learn more about See You Now. Visit the ANA Innovation website for additional resources. https://www.nursingworld.org/practice-policy/innovation   If you know a healthcare professional whose work reflects grit, innovation or extraordinary care—or if that story is your own—we encourage you to apply for the TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson, a branded award.   Have questions or feedback for the SEE YOU NOW team? Future episode ideas? Contact us at hello@seeyounowpodcast.com. 

In this episode of The Lead, host Tina Baykaner, MD, MPH, is joined by Christopher Kowalewski, MD, and Marco Perez, MD, to discuss the journal article, Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study. Together, they review findings from this secondary analysis of the LOOP Study and explore the relationship between genetic risk and atrial fibrillation screening. Learning Objectives Review the key findings from the secondary analysis of the randomized LOOP Study examining atrial fibrillation screening according to genetic risk. Discuss the relationship between genetic risk and atrial fibrillation screening as evaluated in the study. Explore the potential implications of incorporating genetic risk into atrial fibrillation screening strategies.   Host: Tina Baykaner, MD, MPH Guests: Christopher Kowalewski, MD and Marco Perez, MD   Disclosures: T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   C. Kowalewski No relevant disclosures   M. Perez Ownership/Partnership/Principal: QALY Honoraria/Speaking/Consulting Fee: Boston Scientific, Biotronik Research: Apple, Inc. Other/Stock Options Privately Held

In this segment of The Charlie James Show, host Charlie James opens by addressing Dr. Anthony Fauci's recent congressional testimony, mockingly noting how Fauci repeatedly pleaded the Fifth Amendment during questioning. James revisits the early days of the pandemic, playing a montage of past statements from prominent public figures and health officials who promised that COVID-19 vaccines would completely halt transmission and end the pandemic—claims James roundly dismisses as political rhetoric. He highlights comments from Dr. Deborah Birx acknowledging that early pandemic restrictions and school closures had become heavily politicized during an election year. The show then opens the phone lines to listeners who share their personal experiences during the pandemic. Richard from Dallas calls in to complain about government workers getting paid during furloughs while private sector workers were forced to rely on unemployment benefits. Louise from Columbus calls to question health complications linked to vaccines and discusses Senator Lindsey Graham's past political support for the Bush family. Finally, Billy from Anderson recounts his personal struggles with contracting COVID-19 multiple times despite taking the Johnson & Johnson vaccine, detailing his frustrating experiences attempting to obtain alternative treatments like Ivermectin from his doctor.

Miguel Ángel González Suárez te presenta el Informativo de Primera Hora en 'El Remate', el programa matinal de La Diez Capital Radio que arranca tu día con: Las noticias más relevantes de Canarias, España y el mundo, analizadas con rigor y claridad. Hoy hace un año: El Gobierno insiste en que presentará los presupuestos pero no aclara si los registrarán: "No me adelanten pantallas" … y hoy hace dos años: Los canarios afiliados a partidos políticos apenas superan los 10.000. Hoy se cumplen 1.623 días de guerra entre Rusia y Ucrania. 4 años y 155 días. Hoy es jueves 30 de julio de 2026. Día Internacional de la Amistad. El 30 de julio se celebra en todo el mundo el Día Internacional de la Amistad, en honor a ese sentimiento desinteresado que es capaz de unir a personas muy diferentes, romper fronteras y tender lazos de solidaridad. Es tan poderoso por su naturaleza misma de bondad e incondicionalidad. El reconocimiento oficial de esta efeméride ha sido iniciativa de la Asamblea General de Naciones Unidas en el año 2011, cuando proclamó el 30 de julio como el Día Internacional de la Amistad, a propuesta de la Cruzada Mundial de la Amistad. El objetivo de la ONU es transmitir este sentimiento como una herramienta para conseguir la paz, acabar con la violencia y la pobreza, contribuyendo a una sociedad más justa y sostenible. En definitiva, que haya armonía dentro de los pueblos y entre ellos. 1626.- Comienzan las obras de construcción de la Universidad de la Sorbona, en París. 1762.- Tropas inglesas ocupan la fortaleza del Morro, en La Habana, pese a la heroica resistencia que ofrecieron los españoles. 1808.- José Bonaparte abandona Madrid precipitadamente al conocer la noticia de la victoria española sobre las tropas francesas en la batalla de Bailén. 1887.- Concluyen los trabajos de cimentación de la parisina torre Eiffel. 1910.- España suspende sus relaciones con El Vaticano, ante la actitud de la Santa Sede, consecuencia de la política de Canalejas en materia religiosa. 1913.- Se prohíben los juegos de azar en España. 1959.- Se constituye la Jefatura Central de Tráfico, embrión de la Dirección General de Tráfico en España. 1976.- El rey Juan Carlos I decreta una amnistía para los delitos políticos y de opinión en España. 1983.- Entra en vigor en España la ley de las 40 horas semanales de trabajo y 30 días de vacaciones al año. 2011.- "El Bulli" cierra sus puertas como restaurante después de 30 años para convertirse en una Fundación. 2020: La estadounidense Johnson & Johnson comienza a probar en humanos su vacuna experimental contra el COVID-19. Patrocinio del santo de cada día por gentileza de la Casa de las Imágenes, en la calle Obispo Perez Cáceres, 17 en Candelaria. Santoral para hoy, 30 de julio: santos Máxima, Pedro Crisólogo, Abdón, Senén y Rufino. EE.UU. y Arabia , atacan en Irak a grupos alineados con Irán y dejan al menos 20 muertos. La cifra de muertos por el terremoto en Japón asciende a 18 mientras continúan las tareas de rescate. Los fuegos de Francia y España se estabilizan mientras los evacuados comienzan a regresar a sus casas. Estabilizados los incendios en Madrid y Ávila, donde vuelven los evacuados, mientras avanza el fuego en Castellón. El Gobierno ve "útil" el indulto a Borràs mientras el PP evita valorarlo y pone el foco en Sánchez. La incertidumbre por la guerra de Irán dispara el precio de la gasolina a las puertas del gran éxodo del verano. Canarias destruye 25.100 empleos en el segundo trimestre, el peor dato de España, y el paro vuelve a subir. La EPA de abril-junio de 2026 concede esa disminución de ocupados, lo que lleva el porcentaje de paro respecto a la población activa a un peor registro que el del primer trimestre del año, en el 11,4%; los parados caen en 600 personas por la potente pérdida de activos, de 25.700, lo que compensa la reducción de puestos de trabajos, en 25.100. El Estado transferirá 7.650 millones a Canarias en 2027, la mayor entrega a cuenta en la historia en las Islas. El conjunto de los territorios recibirá el próximo ejercicio 170.529 millones de euros, un 8,1% más que en 2026. Baleària Canarias une las islas de Tenerife, La Palma y La Gomera con más frecuencias y conexiones más rápidas durante el verano. El trimarán 'Pepita Castellví' y el 'fast ferry Volcán de Tirajana' prestan servicio en las rutas entre Los Cristianos, Santa Cruz de La Palma y San Sebastián de La Gomera. Solo el 11% de los canarios realizó mejoras energéticas en su vivienda en los últimos cinco años. La barrera económica aparta de la rehabilitación al 78% de quienes la necesitan y se intensifica en las Islas por el sobrecoste de importar materiales. España y el Banco Europeo de Inversiones, dispuestos a movilizar hasta 1.000 millones para construir en La Palma el Telescopio de Treinta Metros. La propuesta amplía el compromiso anunciado hace un año por la ministra de Ciencia, Innovación y Universidades, Diana Morant, que contemplaba una aportación pública de 400 millones de euros a través del Centro para el Desarrollo Tecnológico y la Innovación (CDTI). Un día como hoy en 1941 nace Paul Anka, cantante canadiense.

Lindsey Graham’s funeral brought together President Trump, Israeli Prime Minister Netanyahu, and Ukrainian President Zelenskyy. Reuters’s Gram Slattery breaks down what came of it. Republican pollsters are worried that economic frustration is sapping midterm enthusiasm from the GOP base. The Washington Post’s Liz Goodwin explains why party stalwarts are souring on its handling of the economy. New data shows that the number of kids living in big U.S. cities has fallen sharply over the past decade. The Wall Street Journal’s Rachel Ensign joins to discuss why. Plus, a deadly 7.1-magnitude earthquake hit Japan, Johnson & Johnson offered to pay billions to settle lawsuits over its talc products, and a Minnesota law is bringing happy hour to retirement homes. Today’s episode was hosted by Gideon Resnick.

In this episode of the Medical Sales Podcast, Samuel Adeyinka sits down with Kweku Larbie, an immunology sales representative at Johnson & Johnson, to explore what it's really like to sell specialty pharmaceuticals in gastroenterology. Kweku explains how biologic therapies for Crohn's disease and ulcerative colitis differ from traditional pharmaceutical products, why specialty sales comes with greater complexity and higher earning potential, and what it takes to support physicians treating patients with chronic autoimmune diseases. He also shares insights into the launch of Tremfya in gastroenterology, the realities of selling within a highly specialized therapeutic area, and the profound impact these therapies can have on patients' quality of life. This episode is a must listen for anyone interested in specialty pharmaceutical sales, immunology, or advancing into high value medical sales roles. Connect with Steve Gielda: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »

The following article of the Tech industry is: “Breast Cancer Recovery: The Essential Role of Reconstruction” by Víctor Matos, Sr. Commercial Director, Johnson & Johnson MedTech Mexico.

Pennsylvania Democrat Senator John Fetterman has  changed his mind on the filibuster. Sen. Fetterman discusses where he differs from his party lines, including Democratic Socialist efforts around the country. Stephen Miran was appointed by President Trump to the Federal Reserve Board of Governors. Ahead of the central bank's two-day policy meeting, Miran discusses money supply, its relationship to inflation, and the future of United States monetary policy. He's expecting the Fed to hold rates steady. Plus, Sherwin-Williams has reported a quarterly beat, Johnson & Johnson has agreed to pay $5.5B to settle the talc lawsuits that have hung over the stock for years, Cracker Barrel is bringing in a new CEO, and YouTube and Peacock are teaming up.   Stephen Miran - 18:31 Sen. John Fetterman - 34:04   In this episode: Stephen Miran, @SteveMiran John Fetterman, @SenFettermanPA Joe Kernen, @JoeSquawk Becky Quick, @BeckyQuick Cameron Costa, @CameronCostaNY   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carl Quintanilla, Jim Cramer and David Faber led off the show with the extension of the chip sector sell-off as AI jitters sparked buying in other groups: The software sector among the tech winners, while the Dow received a boost from Coca-Cola — whose earnings beat sent the stock to a record high.  Speaking of Dow components, Boeing CEO Kelly Ortberg joined the program to discuss the company's Q2 results and why the stock has slumped over the past twelve months. Also in focus: The anchors discussed where companies' AI capex budgets should fit into your investment strategy, Johnson & Johnson's $5.5 billion talc settlement, Meta-BlackRock AI data center partnership, Apple CEO Tim Cook and incoming CEO John Ternus on the red carpet.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In today's episode, you'll discover: 1.     Why authenticity is an important part of leadership? 2.     What kind of masks do you, the leaders, wear, and what is it costing you? 3.     What Emotional Contagion is and how to Use the Emotional Contagion Effect in Positive Ways? To support these three takeaways, I chose a quote from Theodore Roosevelt: "The best executive is the one who has sense enough to pick good men to do what he wants done, and self-restraint to keep from meddling with them while they do it."  About Frans Campher: Today, my guest is Frans Campher, an executive coach, leadership strategist, and facilitator with over two decades of experience guiding high-performing leaders through the challenges of growth, authenticity, and meaningful impact. As CEO and US President of a global leadership development firm, he has worked with senior executives and teams at companies like BP, Ford Europe, GlaxoSmithKline, Deloitte, Citibank, and Johnson & Johnson. How to Get in Touch with Frans Campher: Email: frans@ildynamics.com Website: https://www.ildynamics.com/ Free Gift: https://teamtrust.ildynamics.com/ Stalk me online! Linktr.ee: https://linktr.ee/conniewhitman Communication Style Assessment (CSA)™:  https://changingthesalesgame.com/communication-style-assessment/

This Day in Legal History: Sonia Sotomayor Advances to the Supreme CourtOn July 28, 2009, the Senate Judiciary Committee voted to approve the nomination of Sonia Sotomayor to the Supreme Court, sending her to the full Senate, which confirmed her the following week. With that confirmation she became the first Hispanic justice—and only the third woman—ever to serve on the Court.Her path to the bench was the stuff of American mythology, and it was central to her nomination. Born in the Bronx to Puerto Rican parents, raised in a housing project, diagnosed with juvenile diabetes at seven and losing her father at nine, she went on to Princeton and Yale Law School, then worked as a Manhattan prosecutor before becoming a federal trial judge and later a judge on the Second Circuit Court of Appeals. As a district judge, she famously issued the injunction that ended the 1994–95 Major League Baseball strike. Her confirmation fight, though, turned heavily on a single phrase from an earlier speech—her remark that a “wise Latina” might, with the richness of her experiences, sometimes reach a better conclusion than someone without them. Critics called it bias; supporters called it an honest acknowledgment that lived experience shapes judgment.In the years since, Sotomayor has become one of the Court's most forceful liberal voices, known for pointed dissents on race, criminal justice, and—fittingly for today—the very “shadow docket” at the center of our lead story. She has been among the sharpest critics of the Court deciding major questions through emergency orders with little briefing and no argument. The significance of July 28, 2009 is both symbolic and substantive: symbolic, in that a woman from a Bronx housing project reached the pinnacle of the American legal system and expanded who Americans see reflected on their highest court; and substantive, in that she has spent her tenure insisting the Court explain itself and show its work—an insistence that lands with particular weight in a week when the justices are again being asked to make consequential law on the emergency docket.The Trump administration has escalated its fight over mail-in voting all the way to the Supreme Court, asking the justices on an emergency basis to let its executive order take effect nationwide. This is the direct sequel to yesterday's story: after the First Circuit refused on Saturday to lift the injunction blocking key parts of the March order, the Justice Department went straight to the high Court, asking it to put that injunction on hold while the litigation continues. The order directs federal agencies to build voter-eligibility lists and to restrict Postal Service delivery of ballots not tied to those lists; a coalition of 23 states and D.C. argues the President simply lacks authority to impose federal rules on elections that the Constitution assigns to states and to Congress. What's notable here is the vehicle. This is an emergency application—part of what critics call the “shadow docket,” where the Court decides consequential questions quickly, often with little briefing and no full argument. Regular listeners will remember the shadow docket as a recurring concern precisely because it lets the Court make major law in the shadows. The justices have told the states to respond by August 3, so a decision could come fast. The significance is that one of the most consequential election-administration questions in years—decided against the administration twice below—is now in the hands of a Supreme Court being asked to act on an emergency timeline, months before the midterms.Trump administration asks Supreme Court to allow mail-in ballot restrictions | ReutersWashington Post · CNBCJohnson & Johnson has announced a $5.5 billion settlement to resolve tens of thousands of lawsuits claiming its talc products caused ovarian cancer—a deal that could finally close out more than a decade of litigation. The settlement would cover roughly 69,000 cases consolidated in New Jersey federal court plus related state cases, amounting to about 99.75% of the remaining talc claims. If you were with us last week, the timing is impossible to miss: just days ago, the federal magistrate judge overseeing those 69,000 cases cast serious doubt on whether the plaintiffs could even prove specific causation, ordering them to explain why their claims shouldn't be dismissed. Days later, J&J puts $5.5 billion on the table. That sequence is a lesson in how litigation leverage works—a favorable evidentiary signal can push a defendant toward a global resolution on its own terms, or embolden it, depending on the read. The mechanics matter: the deal needs acceptance by 95% of the ovarian-cancer claimants and approval from the judge overseeing the federal litigation. And notably, J&J isn't conceding anything—its litigation chief called the claims “meritless,” and the company still denies its talc caused cancer, though it pulled talc-based baby powder from U.S. and Canadian shelves back in 2020. The significance is that after years of trials, appeals, and two failed attempts to offload the liability through bankruptcy, J&J is choosing certainty and closure over continued combat—paying billions to make a decade of litigation risk go away, without ever admitting its product was dangerous.Johnson & Johnson announces $5.5 billion settlement of talc lawsuits | ReutersCBS News · Bloomberg LawA major trial has opened in Nashville, where the state of Tennessee is telling a jury that Meta knew its Instagram platform was harming teenagers and buried the evidence to protect its profits. In opening statements for what's expected to be a seven-week trial in state court, Tennessee's lawyers said Meta's own researchers repeatedly flagged that some teens were using the platform compulsively—linked to eating disorders, depression, and self-harm—yet the company declined to disable engagement features like autoplay, notifications, and infinite scroll, which the state says were designed to keep teens hooked and maximize the ads they saw. Meta's lawyer countered that the company has been transparent about the risks teens face and about the dangerous content it works to find and remove. The legal theory here should sound familiar—it echoes the playbook used against Big Tobacco: the argument that a company's own internal research proves it knew about the harm and chose profit anyway. That's powerful evidence if the jury believes it, which is likely why, according to reporting, there's already been a fight over whether Meta's lawyers tried to keep some of that internal research out. This connects to threads we've followed all month, from the multistate suit seeking enormous penalties to the individual bellwether cases. The significance is that these harm-to-teens claims are now being tested in front of an actual jury, and the outcome will shape how Meta and its peers value the risk—and how aggressively other states and plaintiffs press similar cases.Meta disregarded its own research on teen harm, Tennessee tells jury | ReutersAnd finally, in my column for Bloomberg Tax this week, I use a striking data point—the Miami metro area's cost of living has reportedly now surpassed greater New York City's—to make a case about how we misunderstand what it means to call a state “low tax.” My core argument is that focusing on a single, highly visible tax like the income tax gives you a badly incomplete picture of whether a place is actually affordable, and for whom.Here's the logic. Florida markets itself relentlessly on having no personal income tax, and rankings like the Tax Foundation's competitiveness index put Florida near the top and New York dead last largely on that basis. But I argue that conflates three very different claims: that Florida collects less through income taxes, that households there bear lower total costs, and that residents end up better off. Only the first is clearly true. The costs a state doesn't cover through an income tax don't vanish—they get shifted, recovered through other levies, or pushed into the private market. It's the same principle as a restaurant that offers “free” parking: the cost of that parking is just baked into the price of the food. When Florida forgoes an income tax, residents still pay—through sales and property taxes, fees, sky-high insurance premiums, and services they have to buy privately that other states provide publicly. And because the income tax is the most progressive major revenue source a state has, replacing it with all of that tends to shift the burden down the income ladder.The comparison I keep coming back to is the everyday cost that a public system absorbs in New York but a family pays out of pocket in Florida. New York guarantees every four-year-old a free, full-day pre-K seat; Florida's program funds about 540 instructional hours—roughly three hours a day—leaving working parents to cover the rest. New York's subsidized transit lets many households skip a car entirely. None of these private substitutes—an insurer, a toll road, a childcare provider—charges you less because you earn less, the way an income tax does. So here's the distributional punchline of my piece: Florida's model is a genuinely great deal if you make ten million dollars a year, because avoiding the income tax dwarfs everything else. But for the merely affluent professional making a few hundred thousand—and certainly for middle- and lower-income households—those insurance bills, tuition payments, and housing costs can quietly eat the whole “tax savings.” My bottom line is that any honest discussion of tax competitiveness has to start with comprehensive household-burden metrics across income levels, not a single headline rate—because “low tax” and “affordable” are not the same thing, and treating them as if they were lets officials sell breaks for the wealthy as broad affordability wins.Miami's Cost of Living Shows Income Tax's Limits as a Metric | Bloomberg Tax This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

In this episode, hosts Sameer Berry, MD, and William Chey, MD, speak with Sarah Enslin, PA-C, Vivek Kaul, MD, and Amy Stewart, CRNP, about the benefits of introducing advanced practice providers in practice and how to help them succeed. ·       How can advanced practice providers, or APPs, help overcome access barriers in gastroenterology? 6:54 ·       How can we effectively onboard APPs? 10:24 ·       Is ACG's APP Academy for Clinical Excellence accounting for the fact that different specialties and practices have different requirements? 18:21 ·       What models have worked well for deploying APPs into GI practices? 24:32 ·       What strategies are most effective for APP retention? 29:07 ·       How can we improve professional development for APPs? 42:14 We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro, @sameerkberry and @umfoodoc.  Berry and Chey report no financial disclosures. Stewart reports financial relationships with AbbVie, Ardelyx, Celltrion, Cristcot, Eli Lilly & Co, Exact Sciences, Genentech, Johnson & Johnson, Merck, Mindset Health (Nerva), Nestle Health Science, Pfizer, Phathom Pharmaceuticals, Prometheus Laboratories, Regeneron, Salix Pharmaceuticals, Sanofi and Takeda Pharmaceuticals. Healio could not confirm relevant financial disclosures for Enslin and Kaul at the time of publication.

If the healthcare sector were a country, it would be the fifth largest carbon emitter on the planet. Yet sustainability remains one of the most underdeveloped strategies in healthcare leadership. In this Insight from Episode 104: Practicing Green Health, Shanda Demorest, DNP, RN, PHN, formerly the Senior Director of Network Experience & Solutions at Practice Greenhealth, makes the case that embedding sustainability into healthcare operations and culture is not a separate agenda; it is a patient safety, health equity, and workforce issue all at once. She offers three clear strategies for healthcare leaders ready to act: identify the right channels of appeal to move leadership, engage communities as true partners rather than passive recipients, and mobilize nurses, who are uniquely positioned to lead this work from the inside out.    If you know a healthcare professional whose work reflects grit, innovation, or extraordinary care—or if that story is your own—we encourage you to apply for the TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson, a branded award.   To listen to this Insight clip's full episode, visit the SEE YOU NOW Podcast Episode 104: Practicing Green Health on APPLE, SPOTIFY, YOUTUBE, or your favorite streaming platform.  Learn more about SEE YOU NOW. Visit the ANA Innovation website for additional resources. https://www.nursingworld.org/practice-policy/innovation 

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, joins presenters to honor the winners of Healio's 2026 Disruptive Innovators Awards in hematology and oncology. ·       VK Gadi, MD, PhD, presents the Heath Equity Award to Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES. 2:13 ·       Hansa Bhargava, MD, presents the Lifetime Disruptor Award to Ann H. Partridge, MD, MPH. 4:33 ·       Hansa Bhargava, MD, presents the Healio NextGen Disruptor Award to Colton Frisco Jones, MD. 7:22 ·       Morgan Collier presents the Woman Disruptor of the Year Award to Erin N. Kobetz, PhD, MPH.  9:43 ·       Richard T. Lee, MD, from City of Hope, accepts the Clinical Innovation Award for the National Clinical Trials System. 11:55 ·       Ryne Wilson, DNP, RN, OCN, presents the Advanced Practice Trailblazer Award to Stacy J. Hines-Dowell, DNP, ACGN, FNP-BC, AGN-BC. 14:43 ·       Diana Gelston presents the Patient Voice Award to Crossroads4Hope and its CEO, Amy Sutton. 16:35 ·       Karine Tawagi, MD, presents the Social Media Influencer Award to Eric K. Singhi, MD. 19:26 ·       Justin McDonnell of Johnson & Johnson accepts the Healio Industry Breakthrough Award for Darzalex Faspro (daratumumab and hyaluronidase-fihj). 21:49 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. To learn more about Healio Disruptive Innovators, visit Healio.com/Innovators. Jain reports no relevant financial disclosures.

Crisis Management: What Customers Remember Most A company may not have caused the crisis—but it still owns the customer experience surrounding it. In this episode of The Customer Service Revolution Podcast, Denise Thompson and John DiJulius examine what leaders should do when customers may be at risk, facts are still developing, and the organization's reputation is suddenly on the line. Using recent food-safety concerns and well-known brand crises as examples, they explain why silence, defensiveness, and rigid policies can magnify the original problem—and how a fast, transparent response can help preserve customer trust. The Four Principles of Customer Experience Crisis Management John outlines four actions organizations should take when a crisis occurs: Address the situation immediately. Make the highest-ranking leader the visible face of the response. Take full responsibility for protecting the customer experience. Overcorrect to demonstrate that the organization genuinely cares. Customers do not separate a company from its suppliers, franchisees, distributors, or employees. They remember the brand name connected to the experience—and how that brand responded. What Successful Crisis Responses Have in Common Denise and John revisit several high-profile corporate crises, including Johnson & Johnson's response to the Tylenol poisonings, Domino's reaction to an employee-created viral video, Chipotle's food-safety challenges, and JetBlue's response to severe travel disruptions. The strongest recoveries shared several characteristics: Customer safety came before short-term profits. Leaders communicated quickly and frequently. The organization took visible, decisive action. The crisis led to meaningful operational improvements. Customers were shown what would prevent the problem from happening again. Why Service Recovery Cannot Depend on the Employee You Reach The conversation expands from large-scale crisis management to everyday service recovery. John explains the service recovery paradox: when a company handles a problem exceptionally well, the customer can become more loyal than if the problem had never occurred. But that outcome requires a consistent recovery process. TDG's LEAST model helps employees respond effectively: Listen Allow the customer to explain the situation without interruption, defensiveness, or debate. Empathize Acknowledge what the customer experienced and demonstrate genuine concern. Apologize Take responsibility for the inconvenience or impact, even when the employee or company did not directly create the original problem. Solve Resolve the issue or take ownership of finding someone who can—without forcing the customer to repeat the story to multiple people. Thank Thank the customer for bringing the problem to the organization's attention and creating an opportunity to make it right. Stop Hiding Behind Policy Policies can protect consistency, but they can also prevent employees from using sound judgment. John shares the story of a longtime salon client who was charged for a missed appointment after her husband unexpectedly died. When she questioned the charge, the manager responded, "Sorry, that's our policy." The problem was not an uncaring employee. It was a system that had trained the employee to enforce a rule without giving her the confidence or authority to recognize an obvious exception. Leaders must decide whether onboarding primarily teaches employees what they cannot do—or prepares them to serve customers and one another with judgment, empathy, and ownership. Key Takeaways A company may not have caused a crisis, but it owns the customer experience of that crisis. Customers judge brands by what they do next. Silence allows speculation to control the story. The highest-ranking leader should be visible during a significant crisis. Taking responsibility is different from accepting legal blame. Overcorrecting can demonstrate that customer safety matters more than short-term costs. Employees need a clear service recovery process and enough autonomy to use it. Every transfer forces the customer to relive the problem and often increases frustration. Policies should provide guidance without eliminating judgment and empathy. A crisis can strengthen trust when it produces transparent action and lasting improvement. Memorable Quotes "Customers don't experience your supply chain. They experience your brand." "A company may not have created the problem, but it still owns the customer experience of the problem." "It's never what happens that is the worst thing. It's the cover-up." "Customers rarely judge a brand by whether something went wrong. They judge it by what the brand did next." "Listen like you're wrong." "Whoever gets the initial complaint owns it." "Every time customers have to retell their story, they get angrier." "Remove the word 'policy' from your company's vocabulary." Chapters 00:49 – When your company's name becomes part of the crisis 02:22 – John's destination-wedding revelation 08:40 – Why a supplier's problem becomes your brand's problem 10:19 – Four principles for responding to a crisis 13:05 – What Johnson & Johnson did after the Tylenol poisonings 16:42 – How Domino's confronted a viral reputation crisis 18:30 – Chipotle, food safety, and the cost of responding slowly 19:21 – JetBlue and turning failure into customer protections 24:17 – The service recovery paradox 25:33 – Using the LEAST service recovery model 27:29 – The "Ask Once" ownership promise 29:05 – How leadership attitudes shape customer treatment 33:45 – Why employees should not have to hide behind policy 36:06 – Final lessons for leaders   Links: Storytelling blog:  https://thedijuliusgroup.com/how-to-be-a-more-effective-leader-by-learning-the-best-way-of-storytelling/ ROX Dashboard:  https://thedijuliusgroup.com/rox-dashboard/ The DiJulius Group Methdology: https://thedijuliusgroup.com/x-commandment-methodology/ Company Service Aptitude Test:  https://thedijuliusgroup.com/c-sat-forms/individual-c-sat/ Schedule a Complimentary Call with one of our advisors:  tdg.click/claudia Ask John!  Submit your questions for John, to be aired on future episode:  tdg.click/ask Customer Experience Executive Academy: https://thedijuliusgroup.com/project/cx-executive-academy/ Experience Revolution Membership:  https://thedijuliusgroup.com/membership/ Books:  https://thedijuliusgroup.com/shop/ Contacts:  Lindsey@thedijuliusgroup.com , Claudia@thedijuliusgroup.com If you want to learn how world-class organizations build cultures customers cannot live without, explore The Experience Revolution Membership. Inside the membership you'll gain access to livestream workshops, practical frameworks, and proven strategies used by organizations around the world. Learn more at https://thedijuliusgroup.com/membership/ Learn More If your organization is working to improve customer experience but struggling to connect it to measurable business outcomes, The DiJulius Group can help. Visit: https://thedijuliusgroup.com Listen to more episodes: https://thedijuliusgroup.com/the-customer-service-revolution-podcast/ Subscribe We talk about topics like this each week; be sure to subscribe wherever you listen to podcasts so you don't miss an episode.

This Day in Legal History: Congress Shrinks the Supreme CourtOn July 23, 1866, Congress passed the Judicial Circuits Act, and in doing so did something that sounds almost unimaginable today: it shrank the Supreme Court. The Act provided that the Court would gradually contract from ten justices down to seven, as sitting justices died or retired and their seats simply went unfilled. Yesterday we talked about Franklin Roosevelt's failed attempt to enlarge the Court to overpower it; today's anniversary is the mirror image—Congress reducing the Court's size for pointedly political reasons.The politics were about President Andrew Johnson. Johnson, who had ascended to the presidency after Lincoln's assassination, was locked in a bitter struggle with the Radical Republicans in Congress over Reconstruction. Congress did not trust him, and one thing it was determined to deny him was the power to shape the Supreme Court. By legislating that upcoming vacancies would go unfilled until the Court shrank to seven, Congress effectively stripped Johnson of any Supreme Court appointments. It was court-unpacking as a weapon of inter-branch warfare—using Congress's control over the Court's size not to change its rulings directly, but to lock a distrusted president out of influencing it.The size of the Supreme Court has never been fixed by the Constitution—it's set by statute, and it has ranged from six at the founding up to ten and back down over the country's first century. After Johnson left office, Congress promptly passed the Judiciary Act of 1869 and settled the number at nine, where it has remained ever since. The significance of July 23, 1866 is that it's the clearest historical example of Congress manipulating the Court's very size for immediate political advantage—and, paired with the 1937 court-packing fight, it bookends the story of how the number nine came to feel sacrosanct even though it never actually was. The Court's independence, it turns out, has always rested partly on a political truce about not touching its structure.A Manhattan federal judge is set to weigh today whether to throw out the Justice Department's subpoenas to New York Times journalists who reported on security concerns about President Trump flying on a Qatari-donated Air Force One. This is the next chapter of a story we covered when the subpoenas first landed: they were issued July 10 by the Manhattan U.S. Attorney, and U.S. District Judge Arun Subramanian has paused their enforcement pending this afternoon's hearing. The two sides want very different things. Prosecutors have asked the judge merely to put the subpoenas on hold for a couple of weeks, saying the investigation's next steps could shape his decision; the Times wants them quashed outright, arguing they're designed to harass and intimidate journalists in violation of the First Amendment. The legal backdrop is genuinely unsettled. There is no absolute reporter's privilege under federal law—prosecutors correctly note the First Amendment doesn't categorically excuse reporters from testifying in criminal investigations—but courts have long been wary of subpoenas that function as fishing expeditions to unmask sources. The significance is that this hearing is a concrete test of where that line falls, and it lands amid a broader pattern we've tracked all month of friction between the administration and the press. However Judge Subramanian rules, it will be an early data point on how much protection newsgathering gets when the government wants to know who talked.US judge to weigh New York Times subpoenas over Trump plane reporting | ReutersThe teenager at the center of a closely watched lawsuit blaming social media for his depression and anxiety has dropped his claims against Meta just days before trial. The plaintiff, a 15-year-old known in court papers as R.K.C., had originally sued four companies—Google's YouTube, Meta's Instagram, Snap's Snapchat, and ByteDance's TikTok—alleging their platforms were engineered to be addictive and harmed his mental health. YouTube, TikTok, and Snap all reached confidential settlements earlier, which would have left Meta as the lone defendant when the case went before a Los Angeles jury on July 27. Instead, R.K.C. withdrew, ending the case. Here's why this matters beyond one teenager. His was a “bellwether” case—one of a small set of representative lawsuits chosen from a huge pool of similar claims and tried first, so both sides can see how juries react and use those signals to gauge settlement values across the whole litigation. When a marquee bellwether evaporates right before trial, it sends a message, though an ambiguous one: it could reflect a quiet settlement, a weakness in this particular plaintiff's proof, or simply strategic repositioning. The significance is that the sprawling social-media-harm litigation against these platforms rolls on, but this particular test balloon won't be inflated—depriving both the companies and the thousands of other plaintiffs of a data point they were watching closely.Teen plaintiff suing Meta over mental health harms drops his claims against company days before trial | ReutersA federal judge has cast serious doubt on roughly 69,000 lawsuits claiming that Johnson & Johnson's talc products caused ovarian cancer, warning the plaintiffs they must come forward with better evidence or risk having their cases dismissed. U.S. Magistrate Judge Rukhsanah Singh in Trenton, New Jersey, zeroed in on a problem at the heart of the litigation: causation. In a mass tort like this, plaintiffs generally have to show not just that a product can cause harm in the abstract—”general causation”—but that it caused this particular plaintiff's disease—”specific causation.” Judge Singh noted that two of the plaintiffs' own expert witnesses, testifying in preparation for a set of bellwether trials, conceded they could not rule out other possible causes of the women's cancers. That's a serious admission, because it goes to whether the experts can offer an opinion that's admissible at all under the rules that make judges the “gatekeepers” of scientific testimony. If you've been listening, this should ring a bell—it's the same expert-gatekeeping battleground we saw in the Tylenol-autism case, just cutting the other direction. Here the judge ordered plaintiffs to explain, by November 19, why their cases shouldn't be tossed for lack of an admissible expert opinion tying J&J's talc to their specific cancers. The significance is that after years of litigation, settlements, and failed bankruptcy maneuvers, the whole edifice of these 69,000 claims may hinge on a question of scientific proof—and the judge just signaled the plaintiffs have a real problem.US judge casts doubt on 69,000 cases alleging J&J talc caused cancer | ReutersAnd finally, in a piece I wrote for Forbes this week, I make an argument that runs underneath a lot of the tax stories we've covered lately: the tax code is only as real as its enforcement. My core claim is that defunding the IRS doesn't actually shrink the tax code—it quietly splits it into two.Here's the framing I start with. Washington has a strange way of talking about tax enforcement. Money to help the IRS collect taxes that are already legally owed gets described as spending, waste, or bureaucratic excess—but when Congress cuts that funding and less revenue comes in, the shortfall gets treated like weather, as if it just happened. I think that's exactly backwards. Congress can write whatever rates, deductions, partnership rules, and anti-abuse provisions it likes, but without skilled auditors and functioning technology, a big chunk of those rules becomes purely aspirational.And crucially, that aspiration isn't evenly distributed. For most wage earners, there's almost no room to maneuver: your income is reported by your employer, your taxes are withheld before you ever see the paycheck, and a computer can flag a mismatch without a human ever looking at your return. But wealthier filers and large businesses often operate through partnerships, closely held entities, cross-border transactions, and complex securities arrangements that take specialized expertise and real time to unwind. So my point is that defunding the IRS doesn't create a smaller tax code—it creates two codes: a statutory, basically inescapable one for people whose income is visible, and a negotiated one for people whose finances are complicated enough to delay, obscure, or contest what they owe. Strip out the enforcement capacity, and the nominal rule stays on the books while its practical effect on the highest earners quietly weakens. That's regressive—a backdoor tax cut for the taxpayers best positioned to resist enforcement.There's a new bill, the Stop CHEATERS Act, that would restore enforcement funding, and I think its sponsors are right about the underlying problem. But I argue they should retire the “fair share” language they've wrapped around it. “Fair share” is subjective—reasonable people can argue forever about whether capital gains should get preferential treatment or whether the top rate is too high or too low, and those are legitimate legislative questions. But that's not the issue here. Congress already wrote the laws; taxpayers are already obligated to follow them. The case for funding the IRS isn't about inventing a new standard of fairness after the fact—it's about consistently administering the standards we already have. By leaning on “fair share,” Democrats risk making basic enforcement sound like a partisan redistribution project when the stronger, harder-to-dismiss argument is simply this: if Congress imposes a tax, the government should be funded well enough to collect it. Anything less isn't restraint or a considered policy choice—it's a quiet exemption for those who can afford to fight.The Tax Code Is Only As Real As Its Enforcement | Forbes This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Host: Rasha Al-Lamee Guests: Christina Magnussen Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2559   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartis, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Risk factors and longevity in women and in men  Mythbusters: Smartphone interference with pacemakers, ICDs Host: Rasha Al-Lamee Guests: JP Carpenter, Christina Magnussen Want to watch that episode? Go to: https://esc365.escardio.org/event/2559 Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartiq, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Our Job Is to be Congruent, MaryCay Durrant Ep 79 MaryCay Durrant is a speaker, facilitator, and change leadership and business performance consultant. For 30+ years, she has helped people reorient, from broken playbooks to systems and paradigms that rekindle the human spirit. From "doing, producing, and performing" to being, partnering and growing. MaryCay does this by illuminating a brilliant model, one that is alive in nature. Her work has touched thousands of senior leaders at more than 100 companies including Johnson & Johnson, Deloitte, Pepsi, Hyatt, KPMG. Her Vibrant W.O.R.K. model is simple, refreshing - and it's what we all need today. It reorients people to the truth that we are built for change and optimistic action. And that when we feel stuck or challenged, it's not failure but feedback. For decades she has been asked to find ways to translate her Vibrancy Model to "every human" as our world has become more and more disconnected and machine optimized. She has taken the task to heart and is on a mission to illuminate a vibrant path in life for 50,000 people through podcast interviews by the end of 2026. MaryCay's fresh perspective, practical tools and sense of wonder will help you find and sustain the "congruence" which is calm, purpose and joy we all want. #equinetherapy #theoaks #retreat #barbieheller #marycaydurrant #forgiveness #failure #freedom #podcast #seeonebeautifulsoul

Lift Every Voice and Sing, JohnsonJohnson, arr. Colin Headings - Austin Ahlborn, bassoon and Collin Headings, piano by First Community Church

Hello our Poison Friends! We are back to fill you in on some more shady deeds from Johnson & Johnson's past. We have another Pharma guest appearance in this one, because Amgen was also involved in the synthetic erythropoietin business. Erythropoietin is the hormone released by the kidneys that stimulates red blood cell production. RBCs are produced in the blood marrow within bones. It always amazes me how the various systems of the body team up to keep everything balanced. Unfortunately, anemia (low RBCs/hemoglobin) is a common issue with kidney diseases, those on dialysis, and cancer patients. As such, these pharmaceutical companies sought to create synthetic erythropoietin to sell to these groups of patients. They succeeded and the treatment made billions of dollars in sales over the years. Relieving the effects of anemia in those with these already taxing conditions sounds great, but there were a number of problems. As it turns out, an increase in the hormone (and RBCs as a result) can lead to clotting, strokes, and heart attacks. Even worse, one researcher called the drug Miracle-Gro for tumors. Hundreds of thousands of patients were likely killed as a result of the treatment and J&J's hiding of study results. Thank you to all of our listeners and supporters! We truly appreciate you all! Please feel free to leave a comment or send us a DM!Patreon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/thepoisonersalmanac⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Merch-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://poisonersalmanac.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Poisoner's Almanac IG-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/poisoners_almanac?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Poisoner's Almanac TT-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@poisonersalmanacp?_t=ZT-8wdYQyXhKbm&_r=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Rita McGrath, bestselling author, Columbia Business School professor, sought-after speaker, strategic advisor, and podcast host, joins me on this episode. Rita is a recognized expert in innovation, strategy, and growth, one of the world's Top 10 Management Thinkers, an award-winning academic researcher, and was named by Fast Company as one of the 25 Smartest Women to Follow on Twitter. Her clients include MetLife, Procter & Gamble, Johnson & Johnson, Merck, and many other leading organizations.

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Kenneth Ellenbogen, MD, FHRS, about the journal article, Real-time smartphone alerts during atrial fibrillation episodes with implantable cardiac monitors and wearable devices: SMART-ALERT study. Together, they discuss the study findings and explore the use of real-time smartphone alerts in conjunction with implantable cardiac monitors and wearable devices during atrial fibrillation episodes. Learning Objectives Review the design and key findings of the SMART-ALERT study evaluating real-time smartphone alerts during atrial fibrillation episodes. Discuss the use of implantable cardiac monitors and wearable devices for real-time detection and notification of atrial fibrillation episodes. Explore the potential clinical implications of integrating smartphone alerts with cardiac monitoring technologies.   Host: Michael S. Lloyd, MD, FHRS   Guests: Tina Baykaner, MD, MPH Kenneth A. Ellenbogen, MD, FHRS   Disclosures: M. Lloyd ·      Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other   T. Baykaner ·      Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific ·      Research: NIH, Boston Scientific   K. Ellenbogen ·      Honoraria/Speaking/Consulting Fee: American College of Cardiology, Heart Rhythm Society, Boston Scientific, Medtronic, Inc., Abbott ·      Royalty Income: Wiley-Blackwell, Elsevier

Host Charlie James previews his upcoming interview with South Carolina Democratic Senate candidate Dr. Annie Andrews before revisiting the state's legislative battle over making Ivermectin an over-the-counter medication. Despite the bill passing nearly unanimously in both the House and Senate, it was ultimately sent back to the Agricultural Committee and effectively killed by Representative Davey Hiatt. Drawing on research from Diane Hardy of the Mom and Pop Alliance of South Carolina, James reveals that Representative Hiatt's son, Lander Hiatt, is a registered lobbyist for the Pharmaceutical Research and Manufacturers of America (PhRMA). He suggests that the bill's sudden defeat may have been directly influenced by this deep-seated lobbying connection to major pharmaceutical companies like Pfizer and Johnson & Johnson.

Carl Quintanilla, Jim Cramer and David Faber led off the show with a "Faber Report": Sources tell David that Stripe and Advent International have jointly offered $60.50 per share to acquire PayPal, whose shares surged on that news. The anchors reacted to what Berkshire Hathaway Chairman Warren Buffett told CNBC's Becky Quick exclusively about investing in Alphabet. Speaking of exclusives, BlackRock CEO Larry Fink joined the program for a wide-ranging interview -- discussing earnings, the investment climate and the AI boom. Also in focus: An unexpected decline in June producer prices, Morgan Stanley and Johnson & Johnson earnings, IBM shares coming off their worst day ever, SpaceX shares trading near their IPO price.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include: Clinical trial updates and discussion of how findings may translate into clinical practice and FDA approvals Treatment sequencing and patient selection Step-up dosing and what to expect in terms of toxicity management when using a GPRC5D-targeted therapy with on-target, off-tumor effects Presenters: Jesus Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research  Partner Tennessee Oncology Nashville, Tennessee Amrita Krishnan, MD, FCAP Nason Hollingworth Family Chair in Myeloma Director, Judy and Bernard Briskin Center for Myeloma Professor Hematology/HCT Executive Director of Hematology City of Hope Orange County Irvine, California Content based on an online CME program supported by an educational grant from Johnson & Johnson. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this week's episode of WSJ's Take On the Week, co-hosts Miriam Gottfried and Telis Demos preview earnings from Taiwan's flagship chip maker, TSMC. They also break down why this coming week's earnings from Johnson & Johnson, UnitedHealth Group and Abbott Laboratories won't do much to save healthcare from its negative earnings growth expectations. Then, Miriam and Telis are joined by Christine Short, head of research at Wall Street Horizon, which is part of the financial-services company TMX Group, to decode why analysts' corporate earnings expectations are reaching exuberant highs. They ask: How are companies achieving such strong results without massive revenue growth, and are those gains sustainable? Plus, Short explains how the AI buildout is reshaping corporate efficiency. They also discuss how companies like BJ's Wholesale, FedEx and Nike are managing tariff refunds and what that has meant for consumers. They talk about what to expect from this week's bank earnings, with JPMorgan, Goldman Sachs, Bank of America and others slated to report. Then the hosts examine the broader market's health and what the Late Earnings Report Index, or LERI, which tracks when companies report later than expected, might be signaling about future volatility. This is WSJ's Take On the Week where co-hosts Telis Demos, Heard on the Street's banking and money columnist, and Miriam Gottfried, WSJ's investing and wealth management reporter, cut through the noise and dive into markets, the economy and finance—the big trades, key players and business news ahead. Have an idea for a future guest or episode? How can we better help you take on the week? We'd love to hear from you. Email the show at takeontheweek@wsj.com. To watch the video version of this episode, visit our WSJ Podcasts YouTube channel or the video page of WSJ.com Further Reading Honey, I Shrank the Cash Flow Jet-Fuel Prices Have Plunged but Aren't Resulting in Much Lower Fares Meta Rakes It In, Yet Still Borrows Billions for AI For more coverage of the markets and your investments, head to WSJ.com, WSJ's Heard on The Street Column, and WSJ's Live Markets blog. Sign up for the WSJ's free Markets A.M. newsletter. Follow Miriam Gottfried here and Telis Demos here. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Something happens. The tire goes flat, the layoff comes, test results come back. And then a sentence starts running in the back of your head. That shouldn't have happened. I should weigh less. They shouldn't have fired me. You barely register it. It plays like a radio in another room, and it produces a feeling, and the feeling produces a behavior, and the behavior produces the day you are having. The stress paradox is that the thought causing you the most pain is also the one that feels most obviously true. Of course they shouldn't have fired me. The belief feels like clear sight rather than distortion, and it feels useful, like it is the thing that will finally motivate change. It almost never is.  Treating stress as a condition to be managed rather than a belief or thought to be examined leaves it running. My guest is Andy Bernstein. Andy is the creator of Active Insight and the founder of the Resilience Academy. He is the author of Breaking the Stress Cycle, and he has taught at Wharton Executive Education since 2007, where his sessions have been audience favorites for thousands of leaders. His corporate clients include Merrill Lynch, Morgan Stanley, Johnson & Johnson, Google, Coca-Cola, and Genentech.  Andy built a process for dealing with stress that is seven steps, done on paper. You do not lie on a couch. You do not say a word. In this conversation, he walks through all seven steps live, twice. Challenging the way other people think is something we all do constantly. Challenging your own thinking is something we rarely do.  Some highlights from the episode: 03:32 Losing his father at 14 and his sister at 16  06:00 Byron Katie, The Work, and a job he never meant to leave  08:26 Active Insight  11:07 Field-testing  14:51 Where our idea of stress came from  19:25 Bears, war zones, and the adaptive exception  24:41 "Should" as the argument with reality  29:33 The seven steps, walked through live  30:43 What is negation? 36:50 Running the process on "they shouldn't have fired me"  39:19 The showdown with yourself  43:37 Time doesn't heal wounds. Insight does.  44:34 The Grant Study and not pushing love away  47:00 Doing it in your head, and when that isn't enough  50:47 Won't I become a doormat?  51:09 Flow, not stress  53:49 The psychology of subtraction Enjoy! For show notes and more, visit larryweeks.com/podcasts  

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Prashanthan Sanders, MBBS, PhD, FHRS, about the journal article, Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm. Together, they discuss the study findings and explore the relationship between atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy who are in sinus rhythm.   Learning Objectives: Review the key findings of the study examining atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy and sinus rhythm. Discuss the association between atrial mechanical contraction and cerebrovascular risk in this patient population. Explore the potential clinical implications of assessing atrial mechanical function in patients with transthyretin amyloid cardiomyopathy.   Host: Michael S. Lloyd, MD, FHRS   Guests: Tina Baykaner, MD, MPH Prashanthan Sanders, MBBS, PhD, FHRS   Disclosures: M. Lloyd Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other   T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   P. Sanders Honoraria/Speaking/Consulting Fee: Boston Scientific, Abbott Medical Other Financial Relationships: Medtronic PLC, Pacemate, CathRx Research: Abbott, Becton Dickinson, Calyan Technologies, Ceryx Medical, Biosense Webster, CathRx, HelloAlfred, Medtronic, Inc., Abbott Medical

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This week, we revisit our conversation with Dr. Karyn Gordon (Leadership & Relationship Expert), author of The Three Chairs: How Great Leaders Drive Communication, Performance & Engagement. Karyn is the CEO and co-founder of DK Leadership, a global leadership coaching company whose purpose is developing great leaders at work and home. She has spoken to more than 500,000 people across 17 countries—including Fortune 500 companies, family businesses, entrepreneurs, professional associations, and others.  She is also a media personality & consultant (Good Morning America, Forbes, The New York Times) - and the TV resident Leadership & Relationship Expert for Canada's #1 Talk-Show – Cityline). In 2021, she was nominated for the 29th annual RBC Canadian Women Entrepreneur Award.  Karyn has a Doctorate in Marriage & Family and certifications in Leadership and Emotional Intelligence, Dr. Karyn was invited to collaborate with professors from The Wharton School to develop an EQ training curriculum specifically for family businesses. John Prato, The Consul General of Canada in New York, hosted a reception honoring her work with New York families and organizations. Over the years, she has served as the media spokesperson for Loblaws, Maple Leaf Foods, Johnson & Johnson, Microsoft, eHarmony and UNICEF.  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TPJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Therapeutic Progress and IMPACT in CRC: Expert Guidance on Applying Rapidly Emerging Evidence on Immunotherapy and Molecular, Precision-Based Approaches in CRC Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb, Exelixis, Inc., Johnson & Johnson, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QEA865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Bladder Cancer Breakthroughs Unpacked: Practical Guidance on Bladder-Sparing Innovations, Perioperative Standards, and Multi-Targeted Platforms Across the Disease Spectrum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and World Bladder Cancer Patient Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas and Pfizer, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QSP865. CME/MOC/AAPA credit will be available until June 29, 2027.Continuing the Innovation Story in Prostate Cancer: Novel Advances and Therapeutic Expansions Across Disease Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Prostate Net. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QSP865. CME/MOC/AAPA credit will be available until June 29, 2027.Continuing the Innovation Story in Prostate Cancer: Novel Advances and Therapeutic Expansions Across Disease Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Prostate Net. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TPJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Therapeutic Progress and IMPACT in CRC: Expert Guidance on Applying Rapidly Emerging Evidence on Immunotherapy and Molecular, Precision-Based Approaches in CRC Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb, Exelixis, Inc., Johnson & Johnson, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QEA865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Bladder Cancer Breakthroughs Unpacked: Practical Guidance on Bladder-Sparing Innovations, Perioperative Standards, and Multi-Targeted Platforms Across the Disease Spectrum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and World Bladder Cancer Patient Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas and Pfizer, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QSP865. CME/MOC/AAPA credit will be available until June 29, 2027.Continuing the Innovation Story in Prostate Cancer: Novel Advances and Therapeutic Expansions Across Disease Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Prostate Net. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QEA865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Bladder Cancer Breakthroughs Unpacked: Practical Guidance on Bladder-Sparing Innovations, Perioperative Standards, and Multi-Targeted Platforms Across the Disease Spectrum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and World Bladder Cancer Patient Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas and Pfizer, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QSP865. CME/MOC/AAPA credit will be available until June 29, 2027.Continuing the Innovation Story in Prostate Cancer: Novel Advances and Therapeutic Expansions Across Disease Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Prostate Net. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QEA865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Bladder Cancer Breakthroughs Unpacked: Practical Guidance on Bladder-Sparing Innovations, Perioperative Standards, and Multi-Targeted Platforms Across the Disease Spectrum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and World Bladder Cancer Patient Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas and Pfizer, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

In this live stream episode of Working Forward, Michael Sneed and John Dugan join host Jason Cochran to explore what it means to lead wisely as artificial intelligence reshapes the business landscape. Michael, a 39-year Johnson & Johnson veteran who rose from summer intern to the executive committee, and John, a retired PwC partner with decades of healthcare consulting experience, share what's really happening in boardrooms around AI adoption. Together with Jason, they discuss why human skills like communication, emotional intelligence, and subject matter expertise are becoming more valuable, not less, and how leaders can navigate uncertainty by placing smart bets, leading with culture and values, and staying curious in a rapidly changing world.   Additional Resources: Connect with Michael Sneed on LinkedIn: https://www.linkedin.com/in/msneed1/ Connect with John Dugan on LinkedIn: https://www.linkedin.com/in/john-k-dugan-cpa-mba-970a47b/ Watch the Working Forward Podcast on YouTube: http://www.youtube.com/@Jason.Cochran Connect with Jason on LinkedIn: https://www.linkedin.com/in/jason-d-cochran/ Follow PeopleForward Network on LinkedIn: https://www.linkedin.com/company/peopleforward-network/ Learn more about PeopleForward Network: https://peopleforwardnetwork.com/   Key Takeaways: AI is reshaping leadership, but human skills like communication, emotional intelligence, and deep expertise are more important than ever. Effective AI strategy starts with culture and values, not technology. Smart leaders place many small bets rather than going all in on any single AI approach. The parallels between the early internet era and today's AI moment offer valuable lessons in patience and intentionality. Leading in uncertain times requires curiosity, humility, and a commitment to listening and learning alongside your team.  

The most successful startups do not rely on luck. They build repeatable Legal Risk Systems that help prevent small mistakes from becoming expensive disasters. During Part 2 of our conversation with Phil Crowley, the discussion moved beyond business formation and into a broader challenge facing modern founders: how to manage legal risk in a world increasingly influenced by AI, automation, rapid growth, and limited resources. The lesson was simple but powerful. Legal protection should not be treated as an event. It should be treated as a system. Who Is Phil Crowley? Phil Crowley is the Founder and Managing Partner of Crowley Law LLC. Before launching his own practice, he spent approximately three decades as Assistant General Counsel at Johnson & Johnson, working closely with business leaders, innovators, and technology-focused organizations. His background is particularly unique because he began his professional career as a research physicist before transitioning into law. That combination enables him to bridge the communication gap that often exists between technical founders and legal professionals. Crowley now focuses on helping technology entrepreneurs commercialize innovation while avoiding common legal mistakes that can derail growth. Follow Phil on LinkedIn: https://www.linkedin.com/in/philcrowleynjny/ Legal Risk Systems Start with Process, Not Paperwork Many entrepreneurs believe legal work begins and ends with filing an LLC. That mindset creates blind spots. Legal protection requires ongoing processes that support the business as it evolves. Examples include: Contract review procedures Intellectual property audits Annual compliance reviews Founder agreement updates Vendor documentation These activities create consistency. Without systems, businesses rely on memory. And memory is unreliable. Businesses scale through systems. Risk management is no exception. Legal Risk Systems The AI Temptation One of the most interesting discussions centered on AI-generated legal content. Today, founders can ask an AI platform to generate: Contracts NDAs Service agreements Terms of service Business policies The convenience is undeniable. The risk is equally real. AI generates responses from patterns. It does not understand the specific context of your business. An agreement that worked for another company may be completely inappropriate for yours. Even worse, AI may surface examples that became popular because they were involved in legal disputes. Popularity does not equal quality. The Human Validation AI can accelerate research. It can assist with drafting. It can organize information. What it cannot do is replace professional legal judgment. The most effective workflow is: Use AI for research and preparation. Create a draft framework. Engage qualified legal counsel. Validate assumptions before execution. This approach improves efficiency without increasing unnecessary risk. AI can reduce drafting time, but cannot eliminate legal accountability. Building Relationships Instead of Buying Documents Another recurring theme was relationship-building. Many founders purchase legal templates and assume the problem is solved. The reality is different. Legal value comes from context. An attorney who understands your business can identify risks you may never think to ask about. That understanding develops over time. When lawyers learn: Your customers Revenue model Technology stack Growth strategy Ownership structure They can provide more strategic guidance. That guidance becomes increasingly valuable as the company grows. Legal Risk Systems Help Prevent Founder Disputes Every startup begins with optimism. Very few founders launch businesses expecting future conflict. Yet growth changes circumstances. People change jobs. People relocate. Personal priorities shift. Ownership expectations evolve. Without clear systems governing these transitions, disagreements become personal. Strong startup systems are established: Ownership rules Vesting schedules Decision authority Exit procedures Compensation expectations The goal is not distrust. The goal is clarity. Good agreements preserve relationships because they remove ambiguity. Legal Risk Systems and Specialized Expertise Crowley emphasized the importance of finding specialists rather than generalists. Technology businesses face unique challenges involving: Software ownership Licensing Intellectual property Data protection Investment structures Specialized attorneys encounter these issues regularly. As a result, they often identify risks faster and provide more practical solutions. This mirrors what happens in software development. When a company needs cybersecurity expertise, it seeks specialists. Legal guidance should follow the same principle. Creating an Annual Legal Review Process One practical idea discussed was maintaining regular communication with legal advisors. Many founders wait until a crisis appears. A better approach is creating an annual review process. Topics might include: New business risks Contract changes Hiring plans Funding opportunities Intellectual property developments These conversations often uncover issues while they remain manageable. That proactive mindset transforms legal support from emergency response into strategic planning. Schedule an annual legal review the same way you schedule financial planning sessions. Conclusion Strong businesses are built on repeatable systems. The same principle applies to risk management. Effective Legal Risk Systems combine professional guidance, documented processes, ongoing reviews, and responsible use of AI. Founders who build these systems early gain more than protection—they gain confidence that their company can grow without being undermined by avoidable mistakes. Legal success is rarely about reacting faster. It is about preparing earlier. Stay Connected: Join the Developreneur Community